Clinical Trial Update: A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer [Phase 1]

View source ↗

Summary

Phase I study evaluating the safety, pharmacology, and biology of erlotinib (OSI-774) in combination with FOLFOX-4 and bevacizumab in advanced colorectal cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Mucinous Adenocarcinoma of the Colon
• Mucinous Adenocarcinoma of the Rectum
• Signet Ring Adenocarcinoma of the Colon
• Signet Ring Adenocarcinoma of the Rectum
• Stage Iiic Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Bevacizumab (bevacizumab)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)
• Tarceva (OSI-774) (Erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum | Phase 1 | Status: COMPLETED